GlassScriptPhysician profile
Jordann Olson
NPI 1164063178
$2,115.28
in general payments reported to CMS, 2019-2025
23 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $800 · 2023: $40.34 · 2024: $113 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $973 · Food and Beverage: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $973.00 |
| Food and Beverage | $342.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,158.48 | 2021-2025 | Krystexxa |
| Amarin Pharma, INC. | $97.86 | 2021 | |
| Lilly USA, LLC | $90.39 | 2021 | |
| Abbvie INC. | $87.55 | 2021-2025 | |
| Novo Nordisk INC | $71.21 | 2021 | |
| Genentech, INC. | $69.95 | 2024 | Ocrevus |
| Janssen Pharmaceuticals, INC | $58.93 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $50.42 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.27 | 2021 | |
| Azurity Pharmaceuticals, INC. | $40.34 | 2023 | Triptodur |
| Takeda Pharmaceuticals U.S.A., INC. | $39.80 | 2021-2025 | Hyqvia |
| Astrazeneca Pharmaceuticals LP | $38.72 | 2021 | |
| Merck Sharp & Dohme LLC | $36.79 | 2021 | |
| Eisai INC. | $33.15 | 2021 | |
| Sanofi-Aventis U.S. LLC | $32.61 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $29.53 | 2025 | |
| Esperion Therapeutics, INC. | $26.78 | 2021 | |
| Dendreon Pharmaceuticals LLC | $25.61 | 2024 | Provenge |
| Teva Pharmaceuticals USA, INC. | $19.83 | 2021 | |
| Argenx US, INC. | $17.66 | 2024 | Vyvgart Hytrulo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.65 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.39 | 2021 | |
| Pfizer INC. | $14.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordann Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.